REVOLUTION MEDICINES INC (RVMD)
NASDAQ • Healthcare
Last close at August 10, 2026 at 20:00 UTC
Fundamentals Charts
About REVOLUTION MEDICINES INC
Revolution Medicines, Inc. is a clinical-stage precision oncology biotechnology company listed on NASDAQ as RVMD. The company develops targeted cancer medicines aimed at pathways central to RAS-driven tumors, and its work centers on a pipeline of inhibitors designed for specific signaling proteins and mutation states rather than marketed products.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
REVOLUTION MEDICINES INC's Technical Indicators Summary
RVMD displays a strong bullish technical profile: price is well above short, medium and long-term moving averages and momentum readings are robust, with a high RSI, a large positive MACD and a strongly positive CCI, while OBV confirms heavy accumulation. Trend strength is validated by an ADX above 30 and volatility is moderate, although the upper Bollinger region suggests the stock is trading near extended levels. Technical takeaway: Strong Buy — broad-based momentum, volume and a clear uptrend underpin the bullish stance.
| Indicator | Value |
|---|---|
RSI (14) | 68.16 |
Stochastic %K (14, 3, 3) | 90.22 |
CCI (20) | 223.77 |
WPR (14) | -5.83 |
Momentum (10) | 18.90 |
MFI | 68.71 |
MACD Level (12, 26) | 6.48 |
Bollinger Bands | $172.99 - $204.52 |
ATR (14) | $7.57 (3.66%) |
ADX (14) | 32.20 |
OBV | 146,953,444 |
Classic Pivot Point | $202.51 |
Fibonacci Pivot Point | $202.51 |
Exponential Moving Averages | $122.84 - $195.68(5 indicators) |
Simple Moving Averages | $119.82 - $192.76(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
RVMD finished the previous session with a subtle upward move, ending at 206.97. RVMD and BeOne partner to develop oncology combo therapies for RAS-addicted cancers.
Trading Volume
Below 10d avg (1.9M)
1.8M
vs S&P 500 Today
Outperforming Market
+0.95%
52-Week Position
Near highs
99%
Updated: August 11, 2026 at 12:27 UTC
Quote Summary
RVMD Headlines
Tom Steyer backs select biotech names
May 2, 2026